AppOmni and Cisco Partner to Extend SaaS Security with End-to-End Zero Trust From Endpoint to the Application

San Mateo, Calif., United States:   AppOmni, the leader in SaaS security today announced a significant partnership that combines the company’s

READ MORE

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Shanghai, China & JERSEY CITY, N.J., United States:   Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the

READ MORE

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in

READ MORE